Treating Stage 4 Melanoma: Immunotherapy, Targeted Therapy, and More

Stage 4 melanoma is the “spread beyond the neighborhood” version of skin cancerand yes, it’s scary.
But it’s also one of the biggest success stories in modern oncology. Over the last decade, treatments like
immunotherapy and targeted therapy have changed what “advanced” can look like, turning some cases into
long-term, manageable conditionsand in a smaller (but very real) group, into durable remissions.

This guide walks through the main treatment options for stage 4 (metastatic) melanoma, how doctors choose
between them, what side effects can show up, and what “more” really means (spoiler: it’s not just chemo).
It’s educationalnot a substitute for your oncology teambecause the best plan depends on your melanoma’s
biology and your body’s priorities.

What “Stage 4” Really Means (and Why It’s Not One-Size-Fits-All)

Stage 4 melanoma (also called metastatic melanoma) means melanoma cells have traveled to distant lymph nodes,
organs, or far-away skin sites. Common destinations include the lungs, liver, brain, bones, and distant skin/lymph nodes.
But the word “stage” doesn’t capture the full storystage 4 can range from a few small spots to widespread disease.

The three big questions doctors try to answer

• Where is it? (including the brain, which needs special planning)
• How fast is it moving? (symptoms, tumor burden, lab markers, scan pace)
• What genetic switches are driving it? (especially BRAF, sometimes KIT/NRAS and others)

Tests that shape the plan

Treatment decisions often start with a biopsy (or prior tissue) plus molecular testing. The most common “actionable”
mutation in cutaneous melanoma is BRAF V600 (often V600E or V600K). If it’s present, targeted therapy becomes an option.
Even if it’s not, immunotherapy can still be very effective.

Your team may also order brain imaging (often MRI), baseline labs, and sometimes special testing depending on melanoma subtype
(for example, mucosal or acral melanomas may be more likely to have KIT alterations, which can open different targeted options).

The Two Heavy Hitters: Immunotherapy and Targeted Therapy

If stage 4 melanoma treatment were a toolbox, immunotherapy and targeted therapy are the power tools.
Surgery and radiation still matter (more on that soon), but systemic therapy is usually the backbone because melanoma can be
a “seen and unseen” diseasemeaning scans may not catch every microscopic cell.

Immunotherapy: Getting Your Immune System Back on the Job

Think of immunotherapy like removing the “Do Not Disturb” sign from your immune system. Melanoma is good at using immune checkpoints
(molecular brakes) to hide in plain sight. Checkpoint inhibitors block those brakes so T-cells can recognize and attack cancer cells.

PD-1 inhibitors (often first-line)

Pembrolizumab (Keytruda) and nivolumab (Opdivo) are PD-1 inhibitors commonly used for unresectable or metastatic melanoma.
They’re typically given by IV infusion on a schedule (often every few weeks), and they can produce durable responses in some patients.

Why doctors like PD-1 inhibitors: for many people, they balance meaningful effectiveness with a side-effect profile that can be manageable
with close monitoring. The tradeoff is that responses can take timesometimes weeks to monthsand not everyone responds.

PD-1 + CTLA-4 combination (nivolumab + ipilimumab)

Ipilimumab (Yervoy) targets CTLA-4, another checkpoint. Pairing CTLA-4 and PD-1 blockade (often nivolumab + ipilimumab)
can increase the chance of a strong responseespecially in higher-risk situationsbut it also increases the risk of immune-related side effects.

Many oncology teams consider this combo when they want the highest probability of deep tumor shrinkage, or when certain clinical features suggest
a more aggressive approach. The “price” is a higher likelihood of needing steroids or treatment breaks if inflammation flares up in organs like the colon,
liver, lungs, or endocrine glands.

PD-1 + LAG-3 combination (nivolumab + relatlimab / Opdualag)

Opdualag combines nivolumab (PD-1) with relatlimab (a LAG-3 inhibitor). LAG-3 is another immune checkpoint that can help
tumors shut down T-cells. Blocking both can improve outcomes compared with PD-1 alone in some patients, with toxicity generally falling between PD-1 alone
and the more intense PD-1 + CTLA-4 combo.

In plain English: it’s a “two-checkpoint” strategy that may offer a solid middle lanestronger than PD-1 alone for some people, but often easier to tolerate
than the ipilimumab-containing combo.

Oncolytic virus therapy (T-VEC) and other immune approaches

Some stage 4 situations involve tumors that can be injected (skin or superficial lymph node lesions). T-VEC (talimogene laherparepvec) is an
oncolytic virus therapy designed to infect and destroy tumor cells and stimulate immune activity locally. It’s not the go-to choice for widespread organ metastases,
but it can play a role in select scenariossometimes alongside other treatments.

Older immune treatments like high-dose interleukin-2 (IL-2) are less common today because newer checkpoint inhibitors are generally more practical,
but IL-2 still appears in certain specialized settings, including as part of some cellular therapy protocols.

Tumor-infiltrating lymphocyte (TIL) therapy: lifileucel (Amtagvi)

One of the most exciting “more” options is TIL therapy. In 2024, the FDA granted accelerated approval to lifileucel (Amtagvi)
for adults with unresectable or metastatic melanoma previously treated with a PD-1 blockerand, if BRAF V600-positive, after BRAF-targeted therapy as well.

TIL therapy uses immune cells taken from a patient’s own tumor, expanded in a lab into billions of cancer-fighting cells, then infused back after a short course
of lymphodepleting chemotherapy. It’s a one-time infusion approach, but it’s intense: it requires a specialized center, careful inpatient/outpatient support, and
monitoring for serious side effects (many tied to the chemo and IL-2 support, as well as low blood counts and infection risk).

Still, for people whose melanoma has already “metabolized” (pun intended) standard immunotherapy, TIL therapy offers a meaningful next option with real response
rates, including some durable control.

Targeted Therapy: Precision Strikes for BRAF-Mutant Melanoma

Targeted therapy focuses on specific mutations that act like jammed accelerators inside cancer cells. In melanoma, the major target is the MAPK pathway,
especially when tumors have a BRAF V600 mutation (roughly about half of melanomas tested, depending on subtype and population).

BRAF + MEK inhibitor combinations

For BRAF-mutant metastatic melanoma, standard targeted therapy typically uses a BRAF inhibitor plus a MEK inhibitor. Common combinations include:

• Dabrafenib + trametinib
• Vemurafenib + cobimetinib
• Encorafenib + binimetinib

Why combine them? Because blocking BRAF alone can work quickly but often leads to resistance; adding a MEK inhibitor improves response and delays resistance.
Targeted therapy can shrink tumors fastsometimes faster than immunotherapywhich matters if symptoms are urgent (pain, organ compromise, rapidly rising disease).

So why not start targeted therapy for everyone with BRAF?

Here’s the strategic twist: while targeted therapy can be fast, immunotherapy can be durable. A major sequencing trial (DREAMseq) in BRAF-mutant metastatic
melanoma found better overall survival when patients started with combination immunotherapy (nivolumab + ipilimumab) and used targeted therapy later if needed,
compared with starting targeted therapy first.

That doesn’t mean targeted therapy is “second best.” It means the order can matter, and the best first move depends on the situation:
if the melanoma is threatening something important right now, quick shrinkage may be the priority. If the disease is stable enough to give immunotherapy
time to work, your team may lean toward starting there for longer-term benefit.

Other targeted options (less common, but important)

Some melanomas (especially mucosal or acral) may have KIT mutations or amplifications. In select cases, KIT inhibitors (such as imatinib)
may be considered. These decisions are highly individualized and usually guided by specialized testing and expert consultation.

When Surgery and Radiation Still Matter in Stage 4

Even in stage 4, local treatments can be valuable. Think of systemic therapy as the “whole-house” plan, while surgery and radiation are the “fix the leaking pipe
before it ruins the floors” plan.

Metastasectomy and “oligometastatic” disease

If melanoma has spread but only to a small number of sites (sometimes called oligometastatic disease), surgery to remove isolated metastases may help with symptom
control and, in select cases, long-term outcomesespecially when combined with systemic therapy.

Brain metastases: a special playbook

Melanoma can spread to the brain, and management often involves a multidisciplinary approach:
stereotactic radiosurgery (SRS) for small lesions, surgery for accessible symptomatic lesions, and systemic therapy (immunotherapy and/or targeted therapy
if BRAF-mutant). Many patients receive combinations over time, tailored to symptoms and scan findings.

How Doctors Choose a First-Line Plan

If you’re hoping there’s a single “best” first treatment, you’re not alone. The truth is more like a personalized chess matchexcept the opponent is a shape-shifting
pile of cells that didn’t read the rulebook.

Common factors that steer the decision

• BRAF status: if BRAF V600-positive, targeted therapy is on the menu (and sequencing becomes a key discussion).
• How urgent the situation is: organ function risk, severe symptoms, rapidly progressive disease may favor faster-acting options.
• Brain involvement: may require integrating SRS/surgery and picking systemic therapy that fits the overall plan.
• Overall health and autoimmune history: affects whether combo immunotherapy is safe or whether a gentler approach is better.
• Patient priorities: time off work, travel distance to infusion center, tolerance for risk, and quality-of-life goals.

A good oncology visit often ends with an actual plan, not just a drug name: “We’ll start with X, scan at Y weeks, manage side effects with Z strategy, and keep
option A/B/C ready depending on response.”

Side Effects: The Part Nobody Puts on the Billboard

Every effective therapy has tradeoffs. The goal is not “zero side effects” (unfortunately, biology didn’t offer that package), but predictable monitoring
and fast action when something changes.

Checkpoint inhibitor side effects (immune-related)

Immunotherapy can cause inflammation in healthy tissues because the immune system gets a little too enthusiasticlike a security guard who tackles the wrong person
because the adrenaline is flowing.

Common issues include rash, itching, diarrhea, fatigue, and joint aches. More serious immune-related adverse events can involve colitis, hepatitis, pneumonitis
(lung inflammation), nephritis (kidney inflammation), and endocrine problems (thyroid, adrenal, pituitary). Many are treatableespecially when caught early.

Call your team promptly for severe diarrhea, shortness of breath, chest pain, yellowing skin/eyes, severe headache, confusion, or sudden weakness.

Targeted therapy side effects (BRAF/MEK)

Targeted therapy side effects often include fever, fatigue, rash, joint pain, diarrhea, and photosensitivity or skin changes depending on the specific combination.
Some people feel the benefits quicklyand also feel side effects quickly. The good news: teams have well-tested strategies for dose holds, supportive meds, and safe
re-starts.

TIL therapy side effects (specialized care)

TIL therapy has a different side-effect timeline. Much of the risk clusters around the lymphodepleting chemotherapy, low blood counts, infection risk, and the IL-2
support after infusion. This is why it’s done at experienced centers with careful monitoring protocols.

Clinical Trials and the “More” in the Title

“More” includes clinical trials testing next-generation checkpoint combinations, personalized cancer vaccines, intratumoral agents, bispecific antibodies, and smarter
ways to combine targeted therapy with immunotherapy. Trials can be especially important if:

• the melanoma doesn’t respond to first-line therapy,
• it responds but then progresses,
• side effects limit standard options, or
• you want access to a promising approach before it becomes widely available.

If you’re considering a trial, ask practical questions: What phase is it? What’s the “standard-of-care” arm? What extra visits are required? Who covers what costs?
And what happens if you need to stop the trial drug?

Supportive Care: Treating the Person, Not Just the Scans

Stage 4 melanoma care isn’t only about tumor shrinkage; it’s also about keeping you living your life while treatment does its job. Supportive care can include:
pain management, anti-nausea meds, physical therapy, nutrition support, skin care guidance, mental health support, and help with sleep and fatigue.

Palliative care is often misunderstood. It’s not “giving up.” It’s an extra layer of support that can be used alongside active treatment to improve
comfort, function, and decision-making. Many cancer centers integrate it early for metastatic disease because it helps people stay stronger for longer.

Conclusion: A More Hopeful (and Strategic) Era for Stage 4 Melanoma

Treating stage 4 melanoma is no longer a single road. It’s a map with multiple routes: immunotherapy (PD-1 alone or in combinations), targeted therapy for BRAF-mutant
disease, local treatments like surgery and radiation when helpful, and newer options like TIL therapy and clinical trials.

The best plan is built around your melanoma’s biology and your lifenot just a guideline flowchart. Bring questions. Bring someone with you to appointments. Write
down side effects early. And remember: in modern melanoma care, “more” is not a vague promiseit’s an expanding set of real choices.

Real-World Experiences: What Patients and Caregivers Often Notice (and Wish They’d Known)

The science of stage 4 melanoma treatment is complicatedbut the lived experience often comes down to a handful of repeating themes. One is that decisions feel urgent,
even when they’re carefully planned. Many patients describe the first few weeks as a blur of scans, lab work, referrals, and new vocabulary. “BRAF,” “PD-1,” and
“infusion schedule” can start to sound like a second language. A practical tip people mention: keep a single notes app page (or notebook) with treatment dates,
side effects, and questions that pop up at 2 a.m.because they always do.

If immunotherapy is the starting point, infusion day itself is often less dramatic than expectedmore “long appointment with snacks” than “movie montage.” The bigger
adjustment can be the uncertainty of timing. Some people feel fine for weeks, then suddenly notice diarrhea, a persistent cough, unusual fatigue, or a rash that wasn’t
invited to the party. Patients who do best often learn one key skill: reporting symptoms early, without trying to tough it out. Clinicians would rather hear “this is
new and weird” on day two than “I’ve had it for two weeks and now it’s on fire.”

For those on BRAF/MEK targeted therapy, the emotional whiplash can be different. Tumors may shrink quickly, which feels like reliefand then side effects like fever or
skin sensitivity can show up and demand attention. Many people learn to treat fever rules as non-negotiable: take temperatures, follow the clinic’s instructions, and
don’t play guessing games with infection risk. Caregivers often become the quiet heroes here, handling logistics (rides, meds, meal plans) and providing a second set of
eyes when fatigue makes everything fuzzy.

Scan anxiety is almost universal. Even when treatment is working, “scan week” can feel like waiting for a jury verdict. Some people cope by scheduling something
comforting after appointmentscoffee with a friend, a favorite meal, a short walk in a parksmall anchors that remind your brain the world still exists outside the
radiology department. Support groups (online or local) can help too, especially when they’re melanoma-specific, because the treatment paths are unique.

Finally, many patients say the most empowering moment is when they realize they have options. Not every option fits every person, but knowing there’s a sequencePlan A,
Plan B, Plan C (and sometimes Plan D)can turn fear into strategy. Asking about mutation testing, brain surveillance, side-effect management plans, and clinical trial
availability doesn’t make you “difficult.” It makes you an informed partner in care. And in stage 4 melanoma treatment, partnership is powerful.

SEO Tags